- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | Medicare will negotiate Novo's GLP-1 drug price. Here's what that means for Ozempic, Wegovy. | ||
| Fr | Novo shares high-dose Wegovy results; Amgen, AstraZeneca drugs get expanded OKs | ||
| Fr | Ozempic, Ibrance among next drugs picked by Medicare for price talks | ||
| Do | 'The bar has risen': China's biotech gains push US companies to adapt | ||
| Do | Roche's new deals head tries to navigate a more 'complicated' and 'expensive' biotech world | ||
| Do | Lilly's Omvoh approved by FDA for Crohn's | ||
| Do | JPM25: The FDA's future, AbbVie's second thoughts and Lilly's lesson | ||
| Mi | At JPM, Biogen CEO tries to take down the deal temperature | ||
| Mi | J&J files a potential blockbuster; Lykos shakes up its board | ||
| Mi | Federal watchdog cites concerns with FDA's accelerated approval process | ||
| Mi | JPM25: Amgen's defense, Merck's patent 'hill' and Viking Therapeutics' long-term planning | ||
| Di | Lilly blames slower-than-expected growth for 2024 sales miss | ||
| Di | Regenxbio licenses gene therapies to Japan's Nippon Shinyaku | ||
| Di | 5 questions facing emerging biotech in 2025 | ||
| 13.01. | JPM25: Deals, Summit's bravado and gene therapy headwinds | ||
| 13.01. | Biogen's 'cold and calculated' offer to buy Sage receives a mixed reaction on Wall Street | ||
| 13.01. | Moderna shares tumble on slashed sales guidance | ||
| 13.01. | Lilly pads cancer drug pipeline with Scorpion deal | ||
| 13.01. | J&J to buy psychiatric drug developer Intra-Cellular for $14.6B | ||
| 13.01. | Lack of regulatory harmonization and other challenges facing clinical services organizations in the APAC market | ||
| 13.01. | Tune raises $175M for hepatitis B medicine, epigenetic research | ||
| 10.01. | Pfizer's PD-1 drug succeeds; AbbVie writes down $3.5B in Cerevel assets | ||
| 10.01. | Patrizia Cavazzoni, key FDA official, to leave agency | ||
| 10.01. | Intellia to stop work on rare disease therapy, lay off staff | ||
| 10.01. | Ouro, backed by GSK, joins hunt to bring bispecifics to autoimmune disease |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
